STOCK TITAN

SpringWorks Therapeutics Inc - SWTX STOCK NEWS

Welcome to our dedicated news page for SpringWorks Therapeutics (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on SpringWorks Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SpringWorks Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SpringWorks Therapeutics's position in the market.

-
-
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
SpringWorks Therapeutics Inc

Nasdaq:SWTX

SWTX Rankings

SWTX Stock Data

3.17B
68.01M
2.69%
107.54%
14.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Stamford

About SWTX

springworks therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. originally conceived by pfizer, springworks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. our name is a reflection of our approach to drug development: we’re springing into action to deliver treatments to people who are in great need and without alternatives.